These findings further highlight the importance of detecting RICTOR amplification or Rictor overexpression in lung cancer, as they may serve as markers of aggressive clinical behavior and therapy sensitivity, especially in cases in which RICTOR amplification is the only targetable oncogenic driver [38]. This evidence concerns the gene RICTOR and lung carcinoma.